BNP/CALL/EDWARDS LIFESCIENCES/110/0.1/20.12.24 | Real-time Boerse Frankfurt Warrants 10:35:23 17/05/2024 pm IST | ||
| 0.22 EUR | -15.38% |
|
| Current month | +52.94% | ||
| 1 month | -31.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.22 | -15.38% |
| 16/24/16 | 0.26 | +4.00% |
| 15/24/15 | 0.25 | +47.06% |
| 14/24/14 | 0.17 | +6.25% |
| 13/24/13 | 0.16 | -11.11% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 10:35 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
BNP Paribas
|
| WKN | PN3Y1Z |
| ISIN | DE000PN3Y1Z9 |
| Date issued | 25/05/2023 |
| Strike | 110 $ |
| Maturity | 20/12/2024 (217 Days) |
| Parity | 10 : 1 |
| Emission price | 0.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.97 € |
|---|---|
| Lowest since issue | 0.06 € |
| Spread | 0.01 € |
| Spread % | 4.35% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
90.11
USD
Average target price
95.9
USD
Spread / Average Target
+6.43%
- Stock Market
- Warrants
- Warrant